Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF

Stefania Notari, Carmine Mancone, Manuel Sergi, Francesca Gullotta, Nazzario Bevilacqua, Massimo Tempestilli, Rocco Urso, Francesco Nicola Lauria, Leopoldo Paolo Pucillo, Marco Tripodi, Paolo Ascenzi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Therapeutic drug monitoring allows to determine the best dosage regimen adapted to each patient optimizing the therapeutic benefits, while minimizing the risk for side effects. Here, the first methodological approach based on matrix-assisted laser desorption/ionization source equipped with tandem time-of-flight (MALDI-TOF/TOF) mass spectrometry for the determination of the antituberculosis (anti-TB) drugs ethambutol, pyrazinamide, rifampicin, and streptomycin concentration in the plasma of tuberculosis-infected patients is reported. The volume of the plasma sample was 200 lL. Plasma samples were cleaned-up by protein precipitation and evaporated in a water bath under a nitrogen stream. The extracted samples were reconstituted with 200 lL of 50% methanol-0.03% formic acid solution (v/v), spiked with known amounts of anti-TB drugs, mixed (1:1) with a saturated matrix solution (4-hydroxybenzoic acid in 50% acetonitrile-0.1% trifluoracetic acid solution; v/v), and spotted onto the MALDI-TOF/TOF sample target plate. The anti-TB drug concentration was determined by standard additions analysis. Regression of standard additions was linear over the whole anti-TB drug concentration range explored (the final anti-TB drug concentration ranged from 0.20 to 200 pmol/μL). The absolute recovery of the anti-TB drugs ranged between 87 and 110%. The minimal ethambu-tol, pyrazinamide, rifampicin, and streptomycin concentration detectable by MALDI-TOF/TOF is 0.08, 0.20, 0.12, and 0.15 pmol/μL, respectively.

Original languageEnglish
Pages (from-to)387-393
Number of pages7
JournalIUBMB Life
Volume62
Issue number5
DOIs
Publication statusPublished - May 2010

Fingerprint

Plasma (human)
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Pharmaceutical Preparations
Pyrazinamide
formic acid
Streptomycin
Rifampin
Plasmas
Ethambutol
Plasma Volume
Drug Monitoring
Baths
Ion sources
Methanol
Mass Spectrometry
Tuberculosis
Lasers
Nitrogen
Mass spectrometry
Desorption

Keywords

  • Antituberculosis drug determination
  • Human plasma
  • MALDI-TOF/TOF

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Clinical Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF. / Notari, Stefania; Mancone, Carmine; Sergi, Manuel; Gullotta, Francesca; Bevilacqua, Nazzario; Tempestilli, Massimo; Urso, Rocco; Lauria, Francesco Nicola; Pucillo, Leopoldo Paolo; Tripodi, Marco; Ascenzi, Paolo.

In: IUBMB Life, Vol. 62, No. 5, 05.2010, p. 387-393.

Research output: Contribution to journalArticle

Notari, Stefania ; Mancone, Carmine ; Sergi, Manuel ; Gullotta, Francesca ; Bevilacqua, Nazzario ; Tempestilli, Massimo ; Urso, Rocco ; Lauria, Francesco Nicola ; Pucillo, Leopoldo Paolo ; Tripodi, Marco ; Ascenzi, Paolo. / Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF. In: IUBMB Life. 2010 ; Vol. 62, No. 5. pp. 387-393.
@article{1b3bdd101d454505889e8b8c741de423,
title = "Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF",
abstract = "Therapeutic drug monitoring allows to determine the best dosage regimen adapted to each patient optimizing the therapeutic benefits, while minimizing the risk for side effects. Here, the first methodological approach based on matrix-assisted laser desorption/ionization source equipped with tandem time-of-flight (MALDI-TOF/TOF) mass spectrometry for the determination of the antituberculosis (anti-TB) drugs ethambutol, pyrazinamide, rifampicin, and streptomycin concentration in the plasma of tuberculosis-infected patients is reported. The volume of the plasma sample was 200 lL. Plasma samples were cleaned-up by protein precipitation and evaporated in a water bath under a nitrogen stream. The extracted samples were reconstituted with 200 lL of 50{\%} methanol-0.03{\%} formic acid solution (v/v), spiked with known amounts of anti-TB drugs, mixed (1:1) with a saturated matrix solution (4-hydroxybenzoic acid in 50{\%} acetonitrile-0.1{\%} trifluoracetic acid solution; v/v), and spotted onto the MALDI-TOF/TOF sample target plate. The anti-TB drug concentration was determined by standard additions analysis. Regression of standard additions was linear over the whole anti-TB drug concentration range explored (the final anti-TB drug concentration ranged from 0.20 to 200 pmol/μL). The absolute recovery of the anti-TB drugs ranged between 87 and 110{\%}. The minimal ethambu-tol, pyrazinamide, rifampicin, and streptomycin concentration detectable by MALDI-TOF/TOF is 0.08, 0.20, 0.12, and 0.15 pmol/μL, respectively.",
keywords = "Antituberculosis drug determination, Human plasma, MALDI-TOF/TOF",
author = "Stefania Notari and Carmine Mancone and Manuel Sergi and Francesca Gullotta and Nazzario Bevilacqua and Massimo Tempestilli and Rocco Urso and Lauria, {Francesco Nicola} and Pucillo, {Leopoldo Paolo} and Marco Tripodi and Paolo Ascenzi",
year = "2010",
month = "5",
doi = "10.1002/iub.321",
language = "English",
volume = "62",
pages = "387--393",
journal = "IUBMB Life",
issn = "1521-6543",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF

AU - Notari, Stefania

AU - Mancone, Carmine

AU - Sergi, Manuel

AU - Gullotta, Francesca

AU - Bevilacqua, Nazzario

AU - Tempestilli, Massimo

AU - Urso, Rocco

AU - Lauria, Francesco Nicola

AU - Pucillo, Leopoldo Paolo

AU - Tripodi, Marco

AU - Ascenzi, Paolo

PY - 2010/5

Y1 - 2010/5

N2 - Therapeutic drug monitoring allows to determine the best dosage regimen adapted to each patient optimizing the therapeutic benefits, while minimizing the risk for side effects. Here, the first methodological approach based on matrix-assisted laser desorption/ionization source equipped with tandem time-of-flight (MALDI-TOF/TOF) mass spectrometry for the determination of the antituberculosis (anti-TB) drugs ethambutol, pyrazinamide, rifampicin, and streptomycin concentration in the plasma of tuberculosis-infected patients is reported. The volume of the plasma sample was 200 lL. Plasma samples were cleaned-up by protein precipitation and evaporated in a water bath under a nitrogen stream. The extracted samples were reconstituted with 200 lL of 50% methanol-0.03% formic acid solution (v/v), spiked with known amounts of anti-TB drugs, mixed (1:1) with a saturated matrix solution (4-hydroxybenzoic acid in 50% acetonitrile-0.1% trifluoracetic acid solution; v/v), and spotted onto the MALDI-TOF/TOF sample target plate. The anti-TB drug concentration was determined by standard additions analysis. Regression of standard additions was linear over the whole anti-TB drug concentration range explored (the final anti-TB drug concentration ranged from 0.20 to 200 pmol/μL). The absolute recovery of the anti-TB drugs ranged between 87 and 110%. The minimal ethambu-tol, pyrazinamide, rifampicin, and streptomycin concentration detectable by MALDI-TOF/TOF is 0.08, 0.20, 0.12, and 0.15 pmol/μL, respectively.

AB - Therapeutic drug monitoring allows to determine the best dosage regimen adapted to each patient optimizing the therapeutic benefits, while minimizing the risk for side effects. Here, the first methodological approach based on matrix-assisted laser desorption/ionization source equipped with tandem time-of-flight (MALDI-TOF/TOF) mass spectrometry for the determination of the antituberculosis (anti-TB) drugs ethambutol, pyrazinamide, rifampicin, and streptomycin concentration in the plasma of tuberculosis-infected patients is reported. The volume of the plasma sample was 200 lL. Plasma samples were cleaned-up by protein precipitation and evaporated in a water bath under a nitrogen stream. The extracted samples were reconstituted with 200 lL of 50% methanol-0.03% formic acid solution (v/v), spiked with known amounts of anti-TB drugs, mixed (1:1) with a saturated matrix solution (4-hydroxybenzoic acid in 50% acetonitrile-0.1% trifluoracetic acid solution; v/v), and spotted onto the MALDI-TOF/TOF sample target plate. The anti-TB drug concentration was determined by standard additions analysis. Regression of standard additions was linear over the whole anti-TB drug concentration range explored (the final anti-TB drug concentration ranged from 0.20 to 200 pmol/μL). The absolute recovery of the anti-TB drugs ranged between 87 and 110%. The minimal ethambu-tol, pyrazinamide, rifampicin, and streptomycin concentration detectable by MALDI-TOF/TOF is 0.08, 0.20, 0.12, and 0.15 pmol/μL, respectively.

KW - Antituberculosis drug determination

KW - Human plasma

KW - MALDI-TOF/TOF

UR - http://www.scopus.com/inward/record.url?scp=77953581278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953581278&partnerID=8YFLogxK

U2 - 10.1002/iub.321

DO - 10.1002/iub.321

M3 - Article

VL - 62

SP - 387

EP - 393

JO - IUBMB Life

JF - IUBMB Life

SN - 1521-6543

IS - 5

ER -